| Literature DB >> 33072835 |
Shashank Bhargava1, Charles McKeever2, George Kroumpouzos3,4,5.
Abstract
The spectrum and magnitude of changes in dermatology practice induced by the COVID-19 pandemic have not been adequately studied.Entities:
Keywords: COVID-19; Dermatology; Hospital service; Practice; Procedures; Teledermatology
Year: 2020 PMID: 33072835 PMCID: PMC7550183 DOI: 10.1016/j.ijwd.2020.09.010
Source DB: PubMed Journal: Int J Womens Dermatol ISSN: 2352-6475
Practice demographics.
| Characteristic | Survey Distribution |
|---|---|
| ≤10 | 330 (45.0) |
| 11–20 | 205 (28.0) |
| >20 | 198 (27.0) |
| Asia | 349 (47.6) |
| North America | 137 (18.7) |
| Central/South America | 131 (17.9) |
| Europe | 102 (13.9) |
| Other | 14 (1.9) |
| Urban | 576 (78.6) |
| Suburban | 137 (18.7) |
| Rural | 20 (2.7) |
| Private | 346 (47.2) |
| Private and hospital | 249 (34.0) |
| Tertiary hospital | 91 (12.4) |
| General hospital | 47 (6.4) |
Percentages are rounded to the decimal place.
Group includes predominantly U.S. participants.
Practice specifics before and during the pandemic.
| Before the pandemic | During the pandemic | ||
|---|---|---|---|
| Characteristic | Survey distribution | Characteristic | Survey distribution |
| Face-to-face consultations only | 542 (73.9) | Face-to-face consultations only | 68 (9.3) |
| TD consultations only | 0 (0) | TD consultations only | 277 (37.8) |
| Face-to-face and TD consultations | 191 (26.1) | Face-to-face and TD consultations | 274 (37.3) |
| Inactive | 0 (0) | Inactive | 114 (15.6) |
| ≤50 | 109 (14.9) | ≤20 | 180 (62.9) |
| 51–100 | 199 (27.2) | 21–40 | 73 (25.5) |
| 101–150 | 180 (24.6) | 41–60 | 14 (4.9) |
| 151–200 | 99 (13.5) | 61–80 | 10 (3.5) |
| 201–250 | 60 (8.2) | 80–100 | 6 (2.1) |
| >250 | 86 (11.7) | >100 | 3 (1.1) |
| ≤20 | 257 (35.1) | Yes | 188 (25.6) |
| 21–40 | 320 (43.7) | ||
| 41–60 | 94 (12.8) | Biopsy | 155 (82.4) |
| 61–80 | 33 (4.5) | Mohs surgery | 61 (32.4) |
| 81–100 | 16 (2.2) | Cryotherapy | 53 (28.2) |
| >100 | 13 (1.8) | Electrosurgery | 53 (28.2) |
| Incision and drainage | 20 (10.6) | ||
| Excision | 19 (10.1) | ||
TD, teledermatology.
Percentages are rounded to the decimal place.
Teledermatology use.
| TD before the pandemic | Survey distribution |
|---|---|
| Yes | 191 (26.1) |
| New | 8 (4.2) |
| Follow-up | 112 (58.6) |
| Both | 71 (37.2) |
| ≤20 | 178 (93.2) |
| 21–40 | 10 (5.2) |
| 41–60 | 3 (1.6) |
| Yes | 551 (75.2) |
| New | 11 (2.0) |
| Follow-up | 171 (31.0) |
| Both | 369 (67.0) |
| ≤20 | 457 (82.9) |
| 21–40 | 72 (13.1) |
| >40 | 22 (4.0) |
| Video | 323 (58.6) |
| Online consultation | 199 (36.1) |
| Phone call | 220 (39.9) |
| Other | 1 (0.2) |
| 269 (48.8) | |
| Zoom | 88 (16.0) |
| Facetime | 83 (15.1) |
| Facebook messenger | 64 (11.6) |
| Viber | 23 (4.2) |
| Other | 74 (13.4) |
| Yes | 251 (45.6) |
| No | 233 (42.3) |
| Sometimes | 67 (12.2) |
| Yes | 476 (64.9) |
| No | 41 (5.6) |
| Do not know | 216 (29.5) |
| Yes | 503 (68.6) |
| No | 213 (29.1) |
| Unsure | 17 (2.3) |
| As part of my regular practice | 402 (79.9) |
| During the COVID-19 pandemic | 294 (58.4) |
| During other health system disruptions | 262 (52.1) |
| ≤20 | 372 (74.0) |
| 21–40 | 98 (19.5) |
| >40 | 33 (6.6) |
CMS, Centers for Medicare and Medicaid Services; HIPAA, Health Insurance Portability and Accountability Act of 1996; TD, teledermatology.
Percentages are rounded to the decimal place.
Statistically significant associations.a
| Practice specifics during the pandemic | Group analyses, n (%) | ||
|---|---|---|---|
| Patients/wk before the pandemic | <.001 | ||
| Years in practice | <.001 | Y/GT | |
| Continent | <.001 | Y/GT: NA (58.4); E (47.0); CSA (30.5); A (4.0) | |
| Procedures/wk before the pandemic | <.001 | <40 (21.7); >40 (40.4) | |
| Continent | <.001 | Y/GT: A (42.8); E (12.5); NA (6.2); CSA (2.5) | |
| Continent | <.001 | NA Median (IQR), 2 (0–50) | |
| Patients/wk before the pandemic | < .001 | >100 Median (IQR), 2 (0–50) | |
| Patients/wk during the pandemic | < .001 | >20 Median (IQR), 4 (0–30) | |
| Number of biopsies postponed/wk | <.001 | ||
| Continent | <.001 | Y/GT: E (38.6); A (26.6); CSA (25.9); NA (16.7) | |
| Continent | <.001 | Y/GT: NA (89.7); E (82.1); CSA (70.2); A (69.4) | |
| TD use before the pandemic | <.001 | ||
| Performing procedures during the pandemic | <.001 | ||
| Taking biopsy during the pandemic | <.001 | ||
| Continent | <.001 | Y/GT: NA (83.9); CSA (77.1); E (63.4); A (60.3) | |
| Patients/wk before the pandemic | <.001 | Y/GT: <100 (77.8); 101–200 (67.3); >200 (59.4) | |
| TD use before the pandemic | <.001 | ||
| TD use during the pandemic | <.001 | ||
| Lockdown | <.001 | Y/GT: Partial (76.8); total (64.4) | |
A, Asia; CSA, Central and South America; E, Europe, GT, group total; HIMG, hospital-issued management guidelines; IQR, interquartile range; NA, North America; TD, teledermatology; Y/GT, yes/group total.
χ2 test performed unless otherwise noted.
Only statistically significant p-values are shown.
Refers to the groups of variables in the second column.
McNemar test.
Percentage rounded to the decimal place. Percentages of groups are listed in descending order.
Wilcoxon rank-sum (Mann Whitney) test.
Spearman rank correlation.
Logistic regression models.
| Model | Dependent variable | Independent variables | LR χ2 | OR | SE | Z | 95% CI | |
|---|---|---|---|---|---|---|---|---|
| 126.98 | ||||||||
| TD before the pandemic | 14.05 | 6.04 | 6.15 | <.001 | 6.05–32.64 | |||
| North America | 2.99 | 0.96 | 3.43 | .001 | 1.60–5.60 | |||
| Performing procedures during the pandemic | 2.12 | 0.58 | 2.74 | .006 | 1.24–3.64 | |||
| Future TD | 1.77 | 0.35 | 2.93 | .003 | 1.21–2.60 | |||
| _cons | 1.06 | 0.16 | 0.37 | .708 | 0.78–1.44 | |||
| 82.00 | ||||||||
| >1000 COVID-19 cases in country | 3.80 | 0.95 | 5.35 | <.001 | 2.33–6.21 | |||
| TD before the pandemic | 2.51 | 0.66 | 3.51 | <.001 | 1.50–4.21 | |||
| TD during the pandemic: Both follow-up and new patients | 2.03 | 0.48 | 3.01 | .002 | 1.28–3.23 | |||
| TD type during the pandemic: Virtual (video) consultation | 1.98 | 0.47 | 2.82 | .004 | 1.23–3.18 | |||
| _cons | 0.55 | 0.13 | –2.58 | .009 | 0.35–0.86 | |||
CI, confidence interval; HIMG, hospital-issued management guidelines; LR, likelihood ratio; OR, odds ratio; PPE, personal protective equipment; SE, standard error; TD, teledermatology.
All LR χ2p < .0001.
Numbers are rounded to two decimal places in all but the p-value column (three decimal places).
z defined as OR:SE.
_cons estimates baseline odds.